Sema BÜYÜKKAPU-BAY, Funda ÇORAPÇIOĞLU, Görkem AKSU, Yonca ANIK, HAKAN DEMİR, Cengiz ERÇİN

Prognostic factors and treatment results of pediatric Hodgkin's lymphoma: A single center experience

Büyükkapu-Bay S, Çorapçıoğlu F, Aksu G, Anık Y, Demir H, Erçin C. Prognostic factors and treatment results of pediatric Hodgkin's lymphoma: A single center experience. Turk J Pediatr 2015; 57: 359-366.The aim of this study was to assess the demographic, clinic data, prognostic factors and treatment/follow-up results of children who were diagnosed with Hodgkin lymphoma and followed in our center of Pediatric Oncology, Kocaeli University Medical Faculty, Kocaeli, Turkey, for 10 years.This retrospective study evaluated 41 patients with Hodgkin lymphoma who were younger than 18 years-old. All patients were treated with risked adapted ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine) chemotherapy and also received involved field radiotherapy. Thirty-two patients (78%) were males and 9 (22%) were females, with a mean age of 10.7±4.0 years. The histopathological diagnosis was mixed cellular type in 51.2% of the patients. B symptoms (unexplained fever, unexplained weight loss, drenching night sweats) were present in 53.7% of the patients and 36.6% of the patients were at advanced stage at the time of the diagnosis. The 3-year overall and event-free survival rates were 88% and 5-year overall and event-free survival rates were 88%, 78%. Age, stage, treatment risk groups, presence of B symptoms and hematological parameters had no significant effect on overall and event-free survival in univariate analysis while bulky disease was the only significant factor on overall survival.Our treatment policy was succesful regarding the similar survival rates in the treatment risk groups, however novel treatment strategies adopting the early response with the reduction of adverse effects are planned in the near future.

PDF

___

1. Kutluk T, Yeşilipek A. Türk Pediatrik Onkoloji Grubu (TPOG), Türk Pediatrik Hematoloji Derneği (TPHD), pediatrik tümör kayıtları. XVII. TPOG Ulusal Pediatrik Kanser Kongresi, Abant-Bolu, 1-5 Mayıs 2012.

2. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues, IARC, Lyon, 2001.

3. Swerdlow S, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008: 321-334.

4. Carbone PP, Kaplan HS, Musshoff K, et al. Report of the committee on Hodgkin's disease staging classification. Cancer Res 1971; 31: 1860-1861.

5. Scheurer ME, Bondy ML, Gurney CG. Epidemiology of childhood cancer. In: Pizzo PA, Poplack DG (eds). Pediatric Oncology (6th ed). Philadelphia: Lippincott Williams&Wilkins; 2011: 638-663.

6. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma. J Natl Compr Canc Netw 2011; 9: 1020- 1058.

7. Grufferman S, Delzell E. Epidemiology of Hodgkin's disease. Epidemiol Rev 1984; 6: 76-106.

8. Hsu SC, Metzger ML, Hudson MM, et al. Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil. Pediatr Blood Cancer 2007; 49: 139-144.

9. Büyükpamukçu M, Varan A, Akyüz C, et al. The treatment of childhood Hodgkin lymphoma: improved survival in a developing country. Acta Oncol 2009; 48: 44-51. 10. Oguz A, Karadeniz C, Okur FV, et al. Prognostic factors and treatment outcome in childhood Hodgkin disease. Pediatr Blood Cancer 2005; 45: 670-675.

11. Sezgin G, Acıpayam C, Özkan A, et al. Hodgkin Lenfoma: Çukurova Deneyimi. XVII. TPOG Ulusal Pediatrik Kanser Kongresi, 1-5 Mayıs 2012, AbantBolu: P213.

12. Tokuç G, Berk B, Özşeker N. Pediatrik Hodgkin lenfoma tanılı hastalarımızın klinik özellikleri ve tedavi sonuçları. XVII. TPOG Ulusal Pediatrik Kanser Kongresi, 1-5 Mayıs 2012, Abant-Bolu: P215.

13. Westergaard T, Melbye M, Pedersen JB, et al. Birth order, sibship size and risk of Hodgkin's disease in children and young adults: a population-based study of 31 million person-years. Int J Cancer 1997; 72:

977-981. 14. Cleary SF, Link MP, Donaldson SS. Hodgkin's disease in the very young. Int J Radiat Oncol Biol Phys 1994; 28: 77-83.

15. Tarbell NJ, Gelber RD, Weinstein HJ, et al. Sex differences in risk of second malignant tumours after Hodgkin's disease in childhood. Lancet 1993; 341: 1428-1432.

16. Gulley ML, Eagan PA, Quintanilla-Martinez L, et al. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: Association with mixed cellularity subtype and Hispanic American ethnicity. Blood 1994; 83: 1595-1602.

17. Harris NL, Jaffe ES, Stein H, et al. A revised EuropeanAmerican classification of lymphoid neoplasms: A proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.

18. Miettinen M, Franssila KO, Saxen E. Hodgkin's disease, lymphocytic predominance nodular. Increased risk for subsequent non-Hodgkin's lymphomas. Cancer 1983; 51: 2293-2300.

19. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004; 45: 1551-1557.

20. Eyre TA, Gatter K, Collins GP, et al. Incidence, management, and outcome of high-grade transformation of nodular lymphocyte predominant hodgkin lymphoma: Long-term outcomes from a 30-year experience. Am J Hematol 2015; Jun 90

21. Al-Mansour M, Connors JM, Gascoyne RD, et al. Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma. J Clin Oncol 2010; 28: 793-799.

22. Bazzeh F, Rihani R, Howard S, et al. Comparing adult and pediatric Hodgkin lymphoma in the surveillance, epidemiology and end results program, 1988-2005: An analysis of 21,734 cases. Leuk Lymphoma 2010; 51: 2198-2207.

23. Miltényi Z, Simon Z, Páyer E, et al. Changing patterns in the clinical pathological features of Hodgkin lymphoma: a report from Debrecen, Hungary. ISRN Hematol 2011: 2011/810708.

24. Ganesan P, Kumar L, Raina V, et al. Hodgkin's lymphoma long-term outcome: an experience from a tertiary care cancer center in North India. Ann Hematol 2011; 90: 1153-1160.

25. Oberlin O, Leverger G, Pacquement H, et al. Lowdose radiation therapy and reduced chemotherapy in childhood Hodgkin's disease: the experience of the French Society of Pediatric Oncology. J Clin Oncol 1992; 10: 1602-1608.

26. Vecchi V, Pileri S, Burnelli R, et al. Treatment of pediatric Hodgkin disease tailored to stage, mediastinal mass, and age. An Italian (AIEOP) multicenter study on 215 patients. Cancer 1993; 72: 2049-2057.

27. Weiner MA, Leventhal B, Brecher ML, et al. Randomized study of intensive MOPP-ABVD with or without lowdose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients: a Pediatric Oncology Group study. J Clin Oncol 1997; 15: 2769-2779.

28. Dörffel W, Lüders H, Rühl U, et al. Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klin Padiatr 2003; 215: 139-145.

29. Rühl U, Albrecht M, Dieckmann K, et al. Responseadapted radiotherapy in the treatment of pediatric Hodgkin's disease: an interim report at 5 years of the German GPOH-HD 95 trial. Int J Radiat Oncol Biol Phys 2001; 51: 1209-1218.

30. Grosjean SG, Oberlin O, Leblanc T, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol 2012; 158: 649-656.

31. Schellong G, Potter R, Bramswig J, et al. High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: The German-Austrian multicenter trial DAL-HD-90 The German-Austrian Pediatric Hodgkin's Disease Study Group. J Clin Oncol 1999; 17: 3736-3744.

32. Smith RS, Chen Q, Hudson MM, et al. Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. J Clin Oncol 2003; 21: 2026-2033.

33. Mauz-Körholz C, Hasenclever D, Dörffel W, et al. Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. J Clin Oncol 2010; 28: 3680- 3686.

34. Landman-Parker J, Pacquement H, Leblanc T, et al. Localized childhood Hodgkin's disease: responseadapted chemotherapy with etoposide, bleomycin, vinblastine, and prednisone before low-dose radiation therapy-results of the French Society of Pediatric Oncology Study MDH90. J Clin Oncol 2000; 18: 1500- 1507.

35. Wolden SL, Chen L, Kelly KM, et al. Long-term results of CCG 5942: a randomized comparison of chemotherapy with and without radiotherapy for children with Hodgkin's lymphoma- a report from the Children's Oncology Group. J Clin Oncol 2012; 30: 3174-3180.

36. Tebbi CK, Mendenhall NP, London WB, et al. Responsedependent and reduced treatment in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children's Oncology Group. Pediatr Blood Cancer 2012; 59: 1259-1265.

37. Schwartz CL, Constine LS, Villaluna D, et al. A riskadapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood 2009; 114: 2051-2059.

38. Kelly KM, Hutchinson RJ, Sposto R, et al. Children's Oncology Group. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704. Ann Oncol 2002; 13: 107-111.

39. Kelly KM, Sposto R, Hutchinson R, et al. BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high-risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood 2011; 117: 2596-2603.

40. Metzger ML, Weinstein HJ, Hudson MM, et al. Association between radiotherapy vs no radiotherapy based on early response to VAMP chemotherapy and survival among children with favorable-risk Hodgkin lymphoma. JAMA 2012; 307: 2609-2616.

41. Hudson MM, Krasin M, Link MP, et al. Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. J Clin Oncol 2004; 22: 4541-4550.

42. Specht L. Prognostic factors in Hodgkin's disease. Cancer Treat Rev 1991; 18: 21-53.

43. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13: 75-78.